{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:40:23Z","timestamp":1788309623019,"version":"build-2803163510"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,14]],"date-time":"2021-01-14T00:00:00Z","timestamp":1610582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,1,14]],"date-time":"2021-01-14T00:00:00Z","timestamp":1610582400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001866","name":"Fonds National de la Recherche Luxembourg","doi-asserted-by":"publisher","award":["FNR\/P13\/6682797"],"award-info":[{"award-number":["FNR\/P13\/6682797"]}],"id":[{"id":"10.13039\/501100001866","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001866","name":"Fonds National de la Recherche Luxembourg","doi-asserted-by":"publisher","award":["INTER\/JPND\/15\/11092422"],"award-info":[{"award-number":["INTER\/JPND\/15\/11092422"]}],"id":[{"id":"10.13039\/501100001866","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013278","name":"EU Joint Programme \u2013 Neurodegenerative Disease Research","doi-asserted-by":"publisher","award":["INTER\/JPND\/15\/11092422"],"award-info":[{"award-number":["INTER\/JPND\/15\/11092422"]}],"id":[{"id":"10.13039\/100013278","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Patient-derived cellular models become an increasingly powerful tool to model human diseases for precision medicine approaches. The identification of robust cellular disease phenotypes in these models paved the way towards high throughput screenings (HTS) including the implementation of laboratory advanced automation. However, maintenance and expansion of cells for HTS remains largely manual work. Here, we describe an integrated, complex automated platform for HTS in a translational research setting also designed for maintenance and expansion of different cell types. The comprehensive design allows automation of all cultivation steps and is flexible for development of methods for variable cell types. We demonstrate protocols for controlled cell seeding, splitting and expansion of human fibroblasts, induced pluripotent stem cells (iPSC), and neural progenitor cells (NPC) that allow for subsequent differentiation into different cell types and image-based multiparametric screening. Furthermore, we provide automated protocols for neuronal differentiation of NPC in 2D culture and 3D midbrain organoids for HTS. The flexibility of this multitask platform makes it an ideal solution for translational research settings involving experiments on different patient-derived cellular models for precision medicine.<\/jats:p>","DOI":"10.1038\/s41598-021-81129-3","type":"journal-article","created":{"date-parts":[[2021,1,14]],"date-time":"2021-01-14T11:11:08Z","timestamp":1610622668000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Integrated, automated maintenance, expansion and differentiation of 2D and 3D patient-derived cellular models for high throughput drug screening"],"prefix":"10.1038","volume":"11","author":[{"given":"Ibrahim","family":"Boussaad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e9rald","family":"Cruciani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Bolognin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Antony","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire M.","family":"Dording","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Jun","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Heutink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenio","family":"Fava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens C.","family":"Schwamborn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rejko","family":"Kr\u00fcger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,14]]},"reference":[{"key":"81129_CR1","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/nrd3480","volume":"10","author":"DC Swinney","year":"2011","unstructured":"Swinney, D. C. & Anthony, J. How were new medicines discovered?. Nat. Rev. Drug Discov. 10, 507\u2013519 (2011).","journal-title":"Nat. Rev. Drug Discov."},{"key":"81129_CR2","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/nrd4336","volume":"13","author":"J Eder","year":"2014","unstructured":"Eder, J., Sedrani, R. & Wiesmann, C. The discovery of first-in-class drugs: Origins and evolution. Nat. Rev. Drug Discov. 13, 577\u2013587 (2014).","journal-title":"Nat. Rev. Drug Discov."},{"key":"81129_CR3","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.neuropharm.2016.03.021","volume":"120","author":"VK Gribkoff","year":"2018","unstructured":"Gribkoff, V. K. & Kaczmarek, L. K. The need for new approaches in CNS drug discovery: Why drugs have failed, and what can be done to improve outcomes. Neuropharmacology 120, 11\u201319 (2018).","journal-title":"Neuropharmacology"},{"key":"81129_CR4","doi-asserted-by":"publisher","first-page":"115239","DOI":"10.1016\/j.bmc.2019.115239","volume":"28","author":"SE Swalley","year":"2020","unstructured":"Swalley, S. E. Expanding therapeutic opportunities for neurodegenerative diseases: A perspective on the important role of phenotypic screening. Bioorg. Med. Chem. 28, 115239 (2020).","journal-title":"Bioorg. Med. Chem."},{"key":"81129_CR5","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1016\/j.chembiol.2019.05.007","volume":"26","author":"A Friese","year":"2019","unstructured":"Friese, A. et al. The convergence of stem cell technologies and phenotypic drug discovery. Cell Chem. Biol. 26, 1050\u20131066 (2019).","journal-title":"Cell Chem. Biol."},{"key":"81129_CR6","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/j.molmed.2018.06.009","volume":"24","author":"KG Chen","year":"2018","unstructured":"Chen, K. G. et al. Pluripotent stem cell platforms for drug discovery. Trends Mol. Med. 24, 805\u2013820 (2018).","journal-title":"Trends Mol. Med."},{"key":"81129_CR7","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1038\/nmeth.1593","volume":"8","author":"G Chen","year":"2011","unstructured":"Chen, G. et al. Chemically defined conditions for human iPSC derivation and culture. Nat. Methods 8, 424\u2013429 (2011).","journal-title":"Nat. Methods"},{"key":"81129_CR8","doi-asserted-by":"publisher","first-page":"759","DOI":"10.2174\/092986710790514480","volume":"17","author":"I Gunaseeli","year":"2010","unstructured":"Gunaseeli, I., Doss, M., Antzelevitch, C., Hescheler, J. & Sachinidis, A. Induced pluripotent stem cells as a model for accelerated patient- and disease-specific drug discovery. Curr. Med. Chem. 17, 759\u2013766 (2010).","journal-title":"Curr. Med. Chem."},{"key":"81129_CR9","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/nrd.2016.245","volume":"16","author":"Y Shi","year":"2017","unstructured":"Shi, Y., Inoue, H., Wu, J. C. & Yamanaka, S. Induced pluripotent stem cell technology: A decade of progress. Nat. Rev. Drug Discov. 16, 115\u2013130 (2017).","journal-title":"Nat. Rev. Drug Discov."},{"key":"81129_CR10","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.copbio.2019.05.011","volume":"60","author":"C Wiegand","year":"2019","unstructured":"Wiegand, C. & Banerjee, I. Recent advances in the applications of iPSC technology. Curr. Opin. Biotechnol. 60, 250\u2013258 (2019).","journal-title":"Curr. Opin. Biotechnol."},{"key":"81129_CR11","doi-asserted-by":"publisher","first-page":"3038","DOI":"10.1093\/brain\/awt224","volume":"136","author":"H Mortiboys","year":"2013","unstructured":"Mortiboys, H., Aasly, J. & Bandmann, O. Ursocholanic acid rescues mitochondrial function in common forms of familial Parkinson\u2019s disease. Brain 136, 3038\u20133050 (2013).","journal-title":"Brain"},{"key":"81129_CR12","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s12929-019-0578-x","volume":"26","author":"C-Y Huang","year":"2019","unstructured":"Huang, C.-Y. et al. Human iPSC banking: Barriers and opportunities. J. Biomed. Sci. 26, 87 (2019).","journal-title":"J. Biomed. Sci."},{"key":"81129_CR13","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/1472-6750-13-102","volume":"13","author":"D Kami","year":"2013","unstructured":"Kami, D. et al. Large-scale cell production of stem cells for clinical application using the automated cell processing machine. BMC Biotechnol. 13, 102 (2013).","journal-title":"BMC Biotechnol."},{"key":"81129_CR14","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/978-1-4939-9624-7_5","volume":"2025","author":"SM Rue","year":"2019","unstructured":"Rue, S. M. et al. A high-throughput system for transient and stable protein production in mammalian cells. Methods Mol. Biol. 2025, 93\u2013142 (2019).","journal-title":"Methods Mol. Biol."},{"key":"81129_CR15","doi-asserted-by":"publisher","first-page":"89","DOI":"10.3390\/ijms21010089","volume":"21","author":"PR Pandey","year":"2019","unstructured":"Pandey, P. R. et al. End-to-end platform for human pluripotent stem cell manufacturing. Int. J. Mol. Sci. 21, 89 (2019).","journal-title":"Int. J. Mol. Sci."},{"key":"81129_CR16","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1038\/s41598-018-34828-3","volume":"9","author":"KIW Kane","year":"2019","unstructured":"Kane, K. I. W. et al. Automated microfluidic cell culture of stem cell derived dopaminergic neurons. Sci. Rep. 9, 1796 (2019).","journal-title":"Sci. Rep."},{"key":"81129_CR17","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.mex.2016.10.005","volume":"3","author":"E Zluhan","year":"2016","unstructured":"Zluhan, E., Kelly, K., LeClair, N., Wortel, D. & Moody, K. Automating hESC differentiation with 3D printing and legacy liquid handling solutions. MethodsX 3, 569\u2013576 (2016).","journal-title":"MethodsX"},{"key":"81129_CR18","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s10616-007-9091-2","volume":"55","author":"RJ Thomas","year":"2007","unstructured":"Thomas, R. J. et al. Manufacture of a human mesenchymal stem cell population using an automated cell culture platform. Cytotechnology 55, 31\u201339 (2007).","journal-title":"Cytotechnology"},{"key":"81129_CR19","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1002\/bit.22187","volume":"102","author":"RJ Thomas","year":"2009","unstructured":"Thomas, R. J. et al. Automated, scalable culture of human embryonic stem cells in feeder-free conditions. Biotechnol. Bioeng. 102, 1636\u20131644 (2009).","journal-title":"Biotechnol. Bioeng."},{"key":"81129_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/srep16647","volume":"5","author":"S Konagaya","year":"2015","unstructured":"Konagaya, S., Ando, T., Yamauchi, T., Suemori, H. & Iwata, H. Long-term maintenance of human induced pluripotent stem cells by automated cell culture system. Sci. Rep. 5, 1\u20139 (2015).","journal-title":"Sci. Rep."},{"key":"81129_CR21","doi-asserted-by":"publisher","first-page":"e59252","DOI":"10.1371\/journal.pone.0059252","volume":"8","author":"P Reinhardt","year":"2013","unstructured":"Reinhardt, P. et al. Derivation and expansion using only small molecules of human neural progenitors for neurodegenerative disease modeling. PLoS ONE 8, e59252 (2013).","journal-title":"PLoS ONE"},{"key":"81129_CR22","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41531-019-0078-4","volume":"5","author":"LM Smits","year":"2019","unstructured":"Smits, L. M. et al. Modeling Parkinson\u2019s disease in midbrain-like organoids. NPJ Park. Dis. 5, 5 (2019).","journal-title":"NPJ Park. Dis."},{"key":"81129_CR23","doi-asserted-by":"publisher","first-page":"4412","DOI":"10.1038\/s41467-018-06515-4","volume":"9","author":"B Readhead","year":"2018","unstructured":"Readhead, B. et al. Expression-based drug screening of neural progenitor cells from individuals with schizophrenia. Nat. Commun. 9, 4412 (2018).","journal-title":"Nat. Commun."},{"key":"81129_CR24","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/s42003-019-0305-x","volume":"2","author":"N Phan","year":"2019","unstructured":"Phan, N. et al. A simple high-throughput approach identifies actionable drug sensitivities in patient-derived tumor organoids. Commun. Biol. 2, 78 (2019).","journal-title":"Commun. Biol."},{"key":"81129_CR25","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/j.stem.2017.01.011","volume":"20","author":"MA Cayo","year":"2017","unstructured":"Cayo, M. A. et al. A drug screen using human iPSC-derived hepatocyte-like cells reveals cardiac glycosides as a potential treatment for hypercholesterolemia. Cell Stem Cell 20, 478-489.e5 (2017).","journal-title":"Cell Stem Cell"},{"key":"81129_CR26","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1002\/sctm.18-0280","volume":"8","author":"Y Kokubu","year":"2019","unstructured":"Kokubu, Y. et al. Phenotypic drug screening for dysferlinopathy using patient-derived induced pluripotent stem cells. Stem Cells Transl. Med. 8, 1017\u20131029 (2019).","journal-title":"Stem Cells Transl. Med."},{"key":"81129_CR27","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1016\/j.stemcr.2018.08.013","volume":"11","author":"V Volpato","year":"2018","unstructured":"Volpato, V. et al. Reproducibility of molecular phenotypes after long-term differentiation to human iPSC-derived neurons: A multi-site omics study. Stem Cell Rep. 11, 897\u2013911 (2018).","journal-title":"Stem Cell Rep."},{"key":"81129_CR28","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1634\/stemcells.2005-0094","volume":"23","author":"A Shahdadfar","year":"2005","unstructured":"Shahdadfar, A., Fr\u00f8nsdal, K., Haug, T., Reinholt, F. P. & Brinchmann, J. E. In vitro expansion of human mesenchymal stem cells: Choice of serum is a determinant of cell proliferation, differentiation, gene expression, and transcriptome stability. Stem Cells 23, 1357\u20131366 (2005).","journal-title":"Stem Cells"},{"key":"81129_CR29","doi-asserted-by":"publisher","first-page":"042317","DOI":"10.1242\/dmm.042317","volume":"13","author":"V Volpato","year":"2020","unstructured":"Volpato, V. & Webber, C. Addressing variability in iPSC-derived models of human disease: guidelines to promote reproducibility. Dis. Model. Mech. 13, 042317 (2020).","journal-title":"Dis. Model. Mech."},{"key":"81129_CR30","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.tiv.2017.07.023","volume":"45","author":"A Wilmes","year":"2017","unstructured":"Wilmes, A. et al. Towards optimisation of induced pluripotent cell culture: Extracellular acidification results in growth arrest of iPSC prior to nutrient exhaustion. Toxicol. In Vitro 45, 445\u2013454 (2017).","journal-title":"Toxicol. In Vitro"},{"key":"81129_CR31","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1038\/s41588-017-0005-8","volume":"50","author":"J Schwartzentruber","year":"2018","unstructured":"Schwartzentruber, J. et al. Molecular and functional variation in iPSC-derived sensory neurons. Nat. Genet. 50, 54\u201361 (2018).","journal-title":"Nat. Genet."},{"key":"81129_CR32","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1089\/ten.2005.11.535","volume":"11","author":"M Kino-Oka","year":"2005","unstructured":"Kino-Oka, M., Ogawa, N., Umegaki, R. & Taya, M. Bioreactor design for successive culture of anchorage-dependent cells operated in an automated manner. Tissue Eng. 11, 535\u2013545 (2005).","journal-title":"Tissue Eng."},{"key":"81129_CR33","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1007\/s00449-016-1659-9","volume":"39","author":"PRT Archibald","year":"2016","unstructured":"Archibald, P. R. T. et al. Comparability of automated human induced pluripotent stem cell culture: A pilot study. Bioprocess Biosyst. Eng. 39, 1847\u20131858 (2016).","journal-title":"Bioprocess Biosyst. Eng."},{"key":"81129_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1472-6750-12-81","volume":"12","author":"H Koike","year":"2012","unstructured":"Koike, H. et al. Establishment of automated culture system for murine induced pluripotent stem cells. BMC Biotechnol. 12, 1 (2012).","journal-title":"BMC Biotechnol."},{"key":"81129_CR35","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1634\/stemcells.2005-0243","volume":"24","author":"A Joannides","year":"2006","unstructured":"Joannides, A. et al. Automated mechanical passaging: A novel and efficient method for human embryonic stem cell expansion. Stem Cells 24, 230\u2013235 (2006).","journal-title":"Stem Cells"},{"key":"81129_CR36","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1038\/nmeth.3507","volume":"12","author":"D Paull","year":"2015","unstructured":"Paull, D. et al. Automated, high-throughput derivation, characterization and differentiation of induced pluripotent stem cells. Nat. Methods 12, 885\u2013892 (2015).","journal-title":"Nat. Methods"},{"key":"81129_CR37","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.cell.2018.09.010","volume":"175","author":"F Soldner","year":"2018","unstructured":"Soldner, F. & Jaenisch, R. Stem cells, genome editing, and the path to translational medicine. Cell 175, 615\u2013632 (2018).","journal-title":"Cell"},{"key":"81129_CR38","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1177\/0163278713499587","volume":"36","author":"KL Grazier","year":"2013","unstructured":"Grazier, K. L., Trochim, W. M., Dilts, D. M. & Kirk, R. Estimating return on investment in translational research: methods and protocols. Eval. Health Prof. 36, 478\u2013491 (2013).","journal-title":"Eval. Health Prof."},{"key":"81129_CR39","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1177\/2211068215609315","volume":"21","author":"S Agrawal","year":"2016","unstructured":"Agrawal, S. et al. Utilizing low-volume aqueous acoustic transfer with the echo 525 to enable miniaturization of qRT-PCR assay. J. Lab. Autom. 21, 57\u201363 (2016).","journal-title":"J. Lab. Autom."},{"key":"81129_CR40","first-page":"1","volume":"2015","author":"LA Mitchell","year":"2015","unstructured":"Mitchell, L. A. et al. qPCRTag analysis: A high throughput, real time PCR assay for Sc2.0 genotyping. J. Vis. Exp. 2015, 1\u20137 (2015).","journal-title":"J. Vis. Exp."},{"key":"81129_CR41","doi-asserted-by":"publisher","first-page":"101870","DOI":"10.1016\/j.scr.2020.101870","volume":"46","author":"SL Nickels","year":"2020","unstructured":"Nickels, S. L. et al. Reproducible generation of human midbrain organoids for in vitro modeling of Parkinson\u2019s disease. Stem Cell Res. 46, 101870 (2020).","journal-title":"Stem Cell Res."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-81129-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-81129-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-81129-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T02:21:36Z","timestamp":1670034096000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-81129-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,14]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["81129"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-81129-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,14]]},"assertion":[{"value":"2 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.B. and J.C.S are co-founders and shareholders of the biotech company OrganoTherapeutics. The other authors declare to have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1439"}}